Natera, which sells non-invasive prenatal DNA tests, filed on Monday with the SEC to raise up to $100 million in an initial public offering.
The San Carlos, CA-based company, which was founded in 2003 and booked $179 million in sales for the 12 months ended March 31, 2015, plans to list on the NASDAQ under the symbol NTRA. Natera initially filed confidentially on May 14, 2014. Morgan Stanley, Cowen & Company and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.
